MARINER: phase III evaluation of rivaroxaban in the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism due to a concurrent disease.

Trial Profile

MARINER: phase III evaluation of rivaroxaban in the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism due to a concurrent disease.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2014

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Registrational; Therapeutic Use
  • Acronyms MARINER
  • Most Recent Events

    • 02 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top